First-trimester screening test for trisomy 21 (Down syndrome), trisomy 18, and open neural tube defects. Risks determined using a combination of first and second-trimester serum markers, with or without first-trimester nuchal translucency measurement. Risks provided after testing is completed for second-trimester specimen, Maternal Serum Screening, Integrated, Specimen #2, Alpha Fetoprotein, hCG, Estriol, and Inhibin A (3000149).
Quantitative Chemiluminescent Immunoassay
Specimen must be drawn between 10 weeks, 0 days and 13 weeks, 6 days gestation. (If gestational age is based on Crown-Rump length (CRL), the specimen must be collected when the CRL is between 32.4-83.9 mm.)
Serum Separator Tube (SST) or Plain Red.
Separate from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP Standard Transport Tube. (Min: 0.3 mL)
Plasma. Hemolyzed specimens.
Submit with Order: Patient's date of birth, current weight, number of fetuses present, patient's race, if the patient was diabetic at the time of conception, if there is a known family history of neural tube defects, if the patient has had a previous pregnancy with a trisomy, if the patient is currently smoking, if the patient is taking valproic acid or carbamazepine (Tegretol), if this is a repeat sample, and the age of the egg donor if in vitro fertilization.
In addition to the above:
If a NT measurement is performed: the date of ultrasound, the CRL measurement, the nuchal translucency (NT) measurement and the name and certification number of the sonographer is required. NT must be measured when the CRL is between 38-83.9 mm.
If no NT measurement is performed: a due date or CRL measurement with the date of ultrasound is required.
The NT measurement must also be performed by an ultrasonographer that is certified by one of the following agencies: Fetal Medicine Foundation (FMF) or Nuchal Translucency Quality Review (NTQR). To avoid possible test delays for an ultrasonographer that is new to our database, please contact the genetic counselor at (800) 242-2787 extension 2141 prior to sending specimen.
After separation from cells: Ambient: 72 hours; Refrigerated: 2 weeks; Frozen: 1 year (Avoid repeated freeze/thaw cycles.)
Refer to report.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
The first specimen of an Integrated Maternal Serum Screening is used to measure PAPP-A. Final interpretative report will be available when the second specimen test results are complete.
|Component Test Code*||Component Chart Name||LOINC|
|0080241||Estimated Due Date||11778-8|
|0080920||Maternal Screen Interpretation||49586-1|
|0080927||Number of Fetuses||11878-6|
|0080932||Maternal Age At Delivery||21612-7|
|0081065||Nuchal Translucency (NT)||12146-7|
|0081069||Sonographer Certification #||49089-6|
|0081158||Family History of Aneuploidy||32435-0|
|0081331||Best date to draw sample #2 by||33882-2|
|3000166||Crown Rump Length||11957-8|
|3000168||Nuchal Translucency (NT), Twin B|
|3000170||Crown Rump Length, Twin B||11957-8|
|3000175||EER Maternal Serum, Integrated, Spcm1||11526-1|
|3000263||Gestational Age Calculated at Collection||18185-9|
- First trimester screen